GE Healthcare has acquired Asymptote Limited, a biotech firm specializing in cryochain technology for sensitive cellular therapies. According to GE Healthcare, “the acquisition of Asymptote fills a critical gap in GE Healthcare’s end-to-end ecosystem of products and services for cell therapy production, and will be an important piece of the portfolio enabling the industrialization of these life-saving therapies”. With this GE Healthcare is betting on cellular therapies advancement in finding treatment for today’s challenging diseases. Earlier, GE Healthcare had invested in Biosafe SA, a cell bioprocessing firm and Vitruvian Network to further its investment in the field of cell therapy and regenerative medicine.
Asymptote is a Cambridge, UK based company that specializes in the development and supply of cryo-chain equipment and consumables for use in regenerative medicine and other biological applications. It was founded in 1990.
About GE Healthcare
GE Healthcare is a subsidiary of the publicly traded US based firm General Electric (NYSE: GE) – a leading medical technologies and services firm. Its products and services include medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions. Founded in 2004, GE Healthcare derived approximately US$ 14.85 billion in revenue (2014) and comprise of more than 46,000 employees worldwide.